Myriad Genetics (MYGN) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Myriad Genetics Reports Fiscal First-Quarter 2016 Financial Results
November 3, 2015 4:06 PM ESTTotal Revenues of $183.5 Million Adjusted Diluted EPS of $0.41 and Diluted EPS of $0.37 Myriad Completes Conversion of Targeted Physicians to myRisk Hereditary Cancer Company Maintains Fiscal Year 2016 Financial Guidance and provides Fiscal Second-Quarter 2016 Financial Guidance
SALT LAKE CITY, Nov. 3, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced financial results for its fiscal first-quarter 2016, provided an update on recent business highlights, maintained its fiscal year 2016 financial guidance and provided fiscal second-quarter 2016 financial guidance.
"We were very... More
